PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-0.10
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
No Data
No Data available this quarter, please select a different quarter.
-11.56
Negative equity while TRAW shows P/B of 0.00. Joel Greenblatt would examine balance sheet repair potential.
-502.16
Negative FCF while TRAW shows P/FCF of 185.06. Joel Greenblatt would examine cash flow improvement potential.
-691.19
Negative operating cash flow while TRAW shows P/OCF of 184.51. Joel Greenblatt would examine operational improvement potential.
-11.56
Negative fair value while TRAW shows ratio of 0.00. Joel Greenblatt would examine valuation model differences.
-250.48%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-0.20%
Negative FCF while TRAW shows yield of 0.54%. Joel Greenblatt would examine cash flow improvement potential.